[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100595524":3},{"organization":4,"armGroups":7,"interventions":15,"overallOfficials":26,"centralContacts":31,"locations":37,"responsibleParty":55,"collaborators":21,"id":58,"slug":21,"hasResults":59,"nctId":60,"briefTitle":61,"officialTitle":61,"acronym":21,"eligibilityCriteria":62,"healthyVolunteers":59,"sex":63,"minAge":64,"maxAge":65,"enrollmentInfo":66,"targetDuration":21,"studyType":69,"phases":70,"briefSummary":72,"conditions":73,"keywords":76,"overallStatus":39,"whyStopped":21,"lastUpdateSubmitDate":81,"lastUpdatePostDateStruct":82,"startDateStruct":85,"completionDateStruct":87,"leadSponsor":89,"locationsCount":90},{"fullName":5,"class":6},"Fujian Medical University","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Hybrid Endoscopic Hemithyroidectomy + Same-Session Contralateral RFA","EXPERIMENTAL","Remote-access gas-less axillo-breast endoscopic hemithyroidectomy with level VI central-neck dissection on the dominant lobe, immediately followed-under the same anesthesia-by ultrasound-guided radiofrequency ablation (17-G, 0.7 cm active tip, 40 W, moving-shot technique) of a ≤ 7 mm contralateral papillary thyroid microcarcinoma.",[13,14],"Procedure: Endoscopic Hemithyroidectomy with Central-Neck Dissection","Procedure: Ultrasound-Guided Radiofrequency Ablation of Contralateral Nodule",[16,22],{"type":17,"name":18,"description":19,"armGroupLabels":20,"otherNames":21},"PROCEDURE","Endoscopic Hemithyroidectomy with Central-Neck Dissection","Gas-less axillo-breast approach (trans-axillary + peri-areolar), carbon-dioxide-free working space, removing dominant thyroid lobe plus level VI lymph nodes; intra-operative neuromonitoring used throughout.",[9],null,{"type":17,"name":23,"description":24,"armGroupLabels":25,"otherNames":21},"Ultrasound-Guided Radiofrequency Ablation of Contralateral Nodule","17-gauge internally-cooled electrode, 0.7 cm active tip, power 40 W; moving-shot technique under real-time ultrasound until hyperechoic halo fully covers ≤ 7 mm papillary microcarcinoma ≥ 2 mm from posterior capsule; same anesthesia session as surgery.",[9],[27],{"name":28,"affiliation":29,"role":30},"Bo Wang MD, Principal Investigator","Fujian Medical University Union Hospital","PRINCIPAL_INVESTIGATOR",[32],{"name":33,"role":34,"phone":35,"phoneExt":21,"email":36},"Bo Wang Professor, MD","CONTACT","+13959123550","wangbo@fjmu.edu.cn",[38],{"facility":29,"status":39,"city":40,"state":41,"zip":42,"country":43,"countryCode":44,"cosmosGeoPoint":45,"geoPoint":50,"contacts":51},"RECRUITING","Fuzhou","Fujian","350001","China","CN",{"type":46,"coordinates":47},"Point",[48,49],119.30611,26.06139,{"lat":49,"lon":48},[52,54],{"name":53,"role":34,"phone":35,"phoneExt":21,"email":36},"Bo Wang Porfessor, MD",{"name":28,"role":30,"phone":21,"phoneExt":21,"email":21},{"type":30,"investigatorFullName":56,"investigatorTitle":57,"investigatorAffiliation":5,"oldNameTitle":21,"oldOrganization":21},"Bo Wang,MD","Director, Head of Thyroid Surgery, Principal Investigator, Clinical Professor","100595524",false,"NCT07033572","Hybrid Endoscopic Hemithyroidectomy and Targeted Ablation for Bilateral Papillary Thyroid Carcinoma","Inclusion Criteria:\n\n* Age 18-65 years.\n* Dominant-side PTC ≤1.5 cm suitable for endoscopic resection.\n* Contralateral nodule ≤7 mm located ≥2 mm from posterior capsule.\n* No radiologic lymph-node metastasis on contralateral side.\n* Written informed consent.\n\nExclusion Criteria:\n\n* Extrathyroidal extension, gross nodal or distant metastasis.\n* Prior neck surgery, prior RFA\u002Fethanol injection, or neck irradiation.\n* Pregnancy or lactation.\n* Serious comorbidities precluding anesthesia or follow-up.","ALL","18 Years","65 Years",{"count":67,"type":68},60,"ESTIMATED","INTERVENTIONAL",[71],"NA","This study evaluates a thyroid-function-preserving alternative to routine total thyroidectomy for bilateral papillary thyroid carcinoma (PTC). Eligible adults undergo remote-access gas-less axillo-breast endoscopic hemithyroidectomy with level VI dissection on the dominant side, followed by ultrasound-guided radiofrequency ablation (RFA) of a ≤7 mm contralateral focus during the same anesthesia. Outcomes include structural-recurrence-free survival, endocrine-function preservation, safety, and quality of life over 24 months.",[74,75],"Thyroid Neoplasms","Carcinoma, Papillary",[77,78,79,80],"Hybrid endoscopic thyroidectomy","Radiofrequency ablation","Thyroid function preservation","Bilateral Thyroid Carcinoma","2025-07-01",{"date":83,"type":84},"2025-07-03","ACTUAL",{"date":86,"type":84},"2018-06-01",{"date":88,"type":68},"2028-06-30",{"name":5,"class":6},1]